Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company ...

Verona Pharma ( (VRNA) ) has released its Q3 earnings. Here is a breakdown of the information Verona Pharma presented to its investors. Verona ...

Verona Pharma isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are ...

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...

Verona Pharma (Nasdaq: VRNA) is already recording millions of dollars in revenue after launching its lead drug in August ...

Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and ...

At the close in NYSE,... ByInvesting.com • Mar 26, 2018 Verona Pharma's RPL554 shows treatment effect in mid-stage CF study; shares up 8% A UK-based Phase 2a clinical trial evaluating Verona ...

Verona Pharma (NASDAQ:VRNA) is scheduled to announce Q3 earnings results on Monday, November 4th, before market open. The consensus EPS Estimate is -$0.41 and the consensus Revenue Estimate is $2.01M.

Mark W. Hahn, the Chief Financial Officer of Verona Pharma plc (NASDAQ:VRNA), recently executed significant stock sales as reported in a filing with the Securities ...

Verona Pharma has been on an incredible upward trajectory, boasting a 91.50% increase year-to-date. In contrast, the MSCI World Index has only managed a 15.50% gain in the same period. This stark ...

Highlights:,Ohtuvayre™ generates $5.6 million in net sales in its first seven weeks, signaling a strong market entry.,October ...